LABELS · 1203ca7f-080c-4c49-e063-6294a90a90e0

SOLU-MEDROL

Open original source → · Download preserved record

Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.

Label effective date: 2024-02-22
Captured: 2026-09-09T23:37:39.774134+00:00
Current indication reconciliation: Not reconciled

Indications and usage: exact source text

INDICATIONS & USAGE When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramuscular use of SOLU-MEDROL Sterile Powder is indicated as follows: Allergic states Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults (intravenous administration only; intramuscular administration is contraindicated), pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic diseases Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, temporal arteritis, polymyositis, and systemic lupus erythematosus.

Full extracted label fields

application numbers

NDA011856

boxed warning exact

brand names

SOLU-MEDROL

current indication status

not_reconciled

dailymed set url

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=74e5060c-8426-1b77-e053-2a91aa0a1f13

generic names

SOLU-MEDROL

1203ca7f-080c-4c49-e063-6294a90a90e0

indications and usage exact

INDICATIONS & USAGE When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramuscular use of SOLU-MEDROL Sterile Powder is indicated as follows: Allergic states Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults (intravenous administration only; intramuscular administration is contraindicated), pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic diseases Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, temporal arteritis, polymyositis, and systemic lupus erythematosus.

indications and usage tables exact

is original packager

manufacturer names

HF Acquisition Co. LLC, DBA HealthFirst

matched search terms

cancer
lymphomas
tumor

package ndcs

51662-1264-2
51662-1264-3
51662-1264-1

product ndcs

51662-1264

product types

HUMAN PRESCRIPTION DRUG

recent major changes exact

record type

complete_spl_indications_section_candidate

routes

INTRAMUSCULAR
INTRAVENOUS

rxcuis

311659

source batch

file

/private/tmp/cancer-full-research/indications/raw/labels-00000.json

Source passages and status connections

Passage classifications are automated and are not treatment recommendations. Connections apply only to their recorded indication scope.

Passage 1 · positive indication candidate

application numbers

NDA011856

brand names

SOLU-MEDROL

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 776
end exclusive: true
exact text: INDICATIONS & USAGE When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramuscular use of SOLU-MEDROL Sterile Powder is indicated as follows: Allergic states Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders Primary or s
label id: 1203ca7f-080c-4c49-e063-6294a90a90e0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 00e900f60d9223601eb11bbc92ed46381adad7b793770517b64e5bb78b5264b5
start: 0

current approval status

not_reconciled

duplicate text group

dup-8bfbfb28593219f9925f

extraction review status

automated_candidate_pending_source_review

generic names

SOLU-MEDROL

ind-span-18e3e0d13b32c8295afa

label id

1203ca7f-080c-4c49-e063-6294a90a90e0

positive predicate support span

end: 272
end exclusive: true
exact text: is indicated
label id: 1203ca7f-080c-4c49-e063-6294a90a90e0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 00e900f60d9223601eb11bbc92ed46381adad7b793770517b64e5bb78b5264b5
start: 260

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 576
end exclusive: true
exact text: INDICATIONS & USAGE When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramuscular use of SOLU-MEDROL Sterile Powder is indicated as follows: Allergic states Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions.
label id: 1203ca7f-080c-4c49-e063-6294a90a90e0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 00e900f60d9223601eb11bbc92ed46381adad7b793770517b64e5bb78b5264b5
start: 0

source url

https://api.fda.gov/drug/label.json?search=id%3A%221203ca7f-080c-4c49-e063-6294a90a90e0%22

spl effective date

2024-02-22

spl set id

74e5060c-8426-1b77-e053-2a91aa0a1f13

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 2 · unclassified context

application numbers

NDA011856

brand names

SOLU-MEDROL

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 943
end exclusive: true
exact text: ate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where ap
label id: 1203ca7f-080c-4c49-e063-6294a90a90e0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 00e900f60d9223601eb11bbc92ed46381adad7b793770517b64e5bb78b5264b5
start: 377

current approval status

not_reconciled

duplicate text group

dup-f232b8100816c14008ff

extraction review status

automated_candidate_pending_source_review

generic names

SOLU-MEDROL

ind-span-b03c0bba2b7f1cd56d32

label id

1203ca7f-080c-4c49-e063-6294a90a90e0

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 743
end exclusive: true
exact text: Dermatologic diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome).
label id: 1203ca7f-080c-4c49-e063-6294a90a90e0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 00e900f60d9223601eb11bbc92ed46381adad7b793770517b64e5bb78b5264b5
start: 577

source url

https://api.fda.gov/drug/label.json?search=id%3A%221203ca7f-080c-4c49-e063-6294a90a90e0%22

spl effective date

2024-02-22

spl set id

74e5060c-8426-1b77-e053-2a91aa0a1f13

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 3 · unclassified context

application numbers

NDA011856

brand names

SOLU-MEDROL

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1326
end exclusive: true
exact text: sickness, transfusion reactions. Dermatologic diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic disorders Acquired (autoimmune) hemoly
label id: 1203ca7f-080c-4c49-e063-6294a90a90e0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 00e900f60d9223601eb11bbc92ed46381adad7b793770517b64e5bb78b5264b5
start: 544

current approval status

not_reconciled

duplicate text group

dup-16b675ab735658d3a335

extraction review status

automated_candidate_pending_source_review

generic names

SOLU-MEDROL

ind-span-5b73f94736ad7c454b93

label id

1203ca7f-080c-4c49-e063-6294a90a90e0

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 1126
end exclusive: true
exact text: Endocrine disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis.
label id: 1203ca7f-080c-4c49-e063-6294a90a90e0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 00e900f60d9223601eb11bbc92ed46381adad7b793770517b64e5bb78b5264b5
start: 744

source url

https://api.fda.gov/drug/label.json?search=id%3A%221203ca7f-080c-4c49-e063-6294a90a90e0%22

spl effective date

2024-02-22

spl set id

74e5060c-8426-1b77-e053-2a91aa0a1f13

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 4 · unclassified context

application numbers

NDA011856

brand names

SOLU-MEDROL

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1475
end exclusive: true
exact text: ticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults (intravenous administr
label id: 1203ca7f-080c-4c49-e063-6294a90a90e0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 00e900f60d9223601eb11bbc92ed46381adad7b793770517b64e5bb78b5264b5
start: 927

current approval status

not_reconciled

duplicate text group

dup-2a767d6181d51c3a6a4c

extraction review status

automated_candidate_pending_source_review

generic names

SOLU-MEDROL

ind-span-0bf82734338ddaf13530

label id

1203ca7f-080c-4c49-e063-6294a90a90e0

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 1275
end exclusive: true
exact text: Gastrointestinal diseases To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis.
label id: 1203ca7f-080c-4c49-e063-6294a90a90e0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 00e900f60d9223601eb11bbc92ed46381adad7b793770517b64e5bb78b5264b5
start: 1127

source url

https://api.fda.gov/drug/label.json?search=id%3A%221203ca7f-080c-4c49-e063-6294a90a90e0%22

spl effective date

2024-02-22

spl set id

74e5060c-8426-1b77-e053-2a91aa0a1f13

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 5 · risk or warning

application numbers

NDA011856

brand names

SOLU-MEDROL

classification reasons

risk_or_warning_words_without_positive_predicate

clinical review status

pending

content role

risk_or_warning

context span

end: 1805
end exclusive: true
exact text: ssociated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults (intravenous administration only; intramuscular administration is contraindicated), pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemothe
label id: 1203ca7f-080c-4c49-e063-6294a90a90e0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 00e900f60d9223601eb11bbc92ed46381adad7b793770517b64e5bb78b5264b5
start: 1076

current approval status

not_reconciled

duplicate text group

dup-dc08b3d3acd568ee1edc

extraction review status

automated_candidate_pending_source_review

generic names

SOLU-MEDROL

ind-span-1acb13ace74817894c0f

label id

1203ca7f-080c-4c49-e063-6294a90a90e0

positive predicate support span

Source null

qualifier mentions

context exact
nd-Blackfan anemia), idiopathic thrombocytopenic purpura in adults (intravenous administration only; intramuscular administrat
kind
age
polarity
not_inferred
span
end
1452
end exclusive
true
exact text
adults
label id
1203ca7f-080c-4c49-e063-6294a90a90e0
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
00e900f60d9223601eb11bbc92ed46381adad7b793770517b64e5bb78b5264b5
start
1446

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 1605
end exclusive: true
exact text: Hematologic disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults (intravenous administration only; intramuscular administration is contraindicated), pure red cell aplasia, selected cases of secondary thrombocytopenia.
label id: 1203ca7f-080c-4c49-e063-6294a90a90e0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 00e900f60d9223601eb11bbc92ed46381adad7b793770517b64e5bb78b5264b5
start: 1276

source url

https://api.fda.gov/drug/label.json?search=id%3A%221203ca7f-080c-4c49-e063-6294a90a90e0%22

spl effective date

2024-02-22

spl set id

74e5060c-8426-1b77-e053-2a91aa0a1f13

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 6 · unclassified context

application numbers

NDA011856

brand names

SOLU-MEDROL

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2010
end exclusive: true
exact text: idiopathic thrombocytopenic purpura in adults (intravenous administration only; intramuscular administration is contraindicated), pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumo
label id: 1203ca7f-080c-4c49-e063-6294a90a90e0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 00e900f60d9223601eb11bbc92ed46381adad7b793770517b64e5bb78b5264b5
start: 1406

current approval status

not_reconciled

duplicate text group

dup-c2bb4f487d7e3f3f2e88

extraction review status

automated_candidate_pending_source_review

generic names

SOLU-MEDROL

ind-span-e29810a277f8939e09a2

label id

1203ca7f-080c-4c49-e063-6294a90a90e0

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 1810
end exclusive: true
exact text: Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy.
label id: 1203ca7f-080c-4c49-e063-6294a90a90e0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 00e900f60d9223601eb11bbc92ed46381adad7b793770517b64e5bb78b5264b5
start: 1606

source url

https://api.fda.gov/drug/label.json?search=id%3A%221203ca7f-080c-4c49-e063-6294a90a90e0%22

spl effective date

2024-02-22

spl set id

74e5060c-8426-1b77-e053-2a91aa0a1f13

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 7 · unclassified context

application numbers

NDA011856

brand names

SOLU-MEDROL

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2088
end exclusive: true
exact text: llaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic diseases Sympathetic ophthalmia, uveitis and ocul
label id: 1203ca7f-080c-4c49-e063-6294a90a90e0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 00e900f60d9223601eb11bbc92ed46381adad7b793770517b64e5bb78b5264b5
start: 1611

current approval status

not_reconciled

duplicate text group

dup-e7e48fb705e90adf307b

extraction review status

automated_candidate_pending_source_review

generic names

SOLU-MEDROL

ind-span-e24aade6541eba5d6238

label id

1203ca7f-080c-4c49-e063-6294a90a90e0

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 1888
end exclusive: true
exact text: Neoplastic diseases For the palliative management of leukemias and lymphomas.
label id: 1203ca7f-080c-4c49-e063-6294a90a90e0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 00e900f60d9223601eb11bbc92ed46381adad7b793770517b64e5bb78b5264b5
start: 1811

source url

https://api.fda.gov/drug/label.json?search=id%3A%221203ca7f-080c-4c49-e063-6294a90a90e0%22

spl effective date

2024-02-22

spl set id

74e5060c-8426-1b77-e053-2a91aa0a1f13

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 8 · unclassified context

application numbers

NDA011856

brand names

SOLU-MEDROL

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2227
end exclusive: true
exact text: ningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic diseases Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases To induce diuresis or remission of proteinuria in idiopa
label id: 1203ca7f-080c-4c49-e063-6294a90a90e0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 00e900f60d9223601eb11bbc92ed46381adad7b793770517b64e5bb78b5264b5
start: 1689

current approval status

not_reconciled

duplicate text group

dup-2b9fac38334eaafc40f1

extraction review status

automated_candidate_pending_source_review

generic names

SOLU-MEDROL

ind-span-d09ba1272143632261ee

label id

1203ca7f-080c-4c49-e063-6294a90a90e0

positive predicate support span

Source null

qualifier mentions

context exact
ltiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy.
kind
biomarker
polarity
not_inferred
span
end
2011
end exclusive
true
exact text
metastatic brain tumor
label id
1203ca7f-080c-4c49-e063-6294a90a90e0
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
00e900f60d9223601eb11bbc92ed46381adad7b793770517b64e5bb78b5264b5
start
1989
context exact
ltiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy.
kind
stage_or_setting
polarity
not_inferred
span
end
2011
end exclusive
true
exact text
metastatic brain tumor
label id
1203ca7f-080c-4c49-e063-6294a90a90e0
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
00e900f60d9223601eb11bbc92ed46381adad7b793770517b64e5bb78b5264b5
start
1989

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 2027
end exclusive: true
exact text: Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy.
label id: 1203ca7f-080c-4c49-e063-6294a90a90e0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 00e900f60d9223601eb11bbc92ed46381adad7b793770517b64e5bb78b5264b5
start: 1889

source url

https://api.fda.gov/drug/label.json?search=id%3A%221203ca7f-080c-4c49-e063-6294a90a90e0%22

spl effective date

2024-02-22

spl set id

74e5060c-8426-1b77-e053-2a91aa0a1f13

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 9 · unclassified context

application numbers

NDA011856

brand names

SOLU-MEDROL

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2355
end exclusive: true
exact text: es For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic diseases Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases Berylliosis, fulminating or disseminated pulmon
label id: 1203ca7f-080c-4c49-e063-6294a90a90e0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 00e900f60d9223601eb11bbc92ed46381adad7b793770517b64e5bb78b5264b5
start: 1828

current approval status

not_reconciled

duplicate text group

dup-343fee39ef8c72d8b075

extraction review status

automated_candidate_pending_source_review

generic names

SOLU-MEDROL

ind-span-019586101cded69f534a

label id

1203ca7f-080c-4c49-e063-6294a90a90e0

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 2155
end exclusive: true
exact text: Ophthalmic diseases Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids.
label id: 1203ca7f-080c-4c49-e063-6294a90a90e0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 00e900f60d9223601eb11bbc92ed46381adad7b793770517b64e5bb78b5264b5
start: 2028

source url

https://api.fda.gov/drug/label.json?search=id%3A%221203ca7f-080c-4c49-e063-6294a90a90e0%22

spl effective date

2024-02-22

spl set id

74e5060c-8426-1b77-e053-2a91aa0a1f13

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 10 · unclassified context

application numbers

NDA011856

brand names

SOLU-MEDROL

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2486
end exclusive: true
exact text: edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic diseases Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptoma
label id: 1203ca7f-080c-4c49-e063-6294a90a90e0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 00e900f60d9223601eb11bbc92ed46381adad7b793770517b64e5bb78b5264b5
start: 1956

current approval status

not_reconciled

duplicate text group

dup-9fbb6837c895178e0233

extraction review status

automated_candidate_pending_source_review

generic names

SOLU-MEDROL

ind-span-2cc2e333dab21d0eade4

label id

1203ca7f-080c-4c49-e063-6294a90a90e0

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 2286
end exclusive: true
exact text: Renal diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus.
label id: 1203ca7f-080c-4c49-e063-6294a90a90e0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 00e900f60d9223601eb11bbc92ed46381adad7b793770517b64e5bb78b5264b5
start: 2156

source url

https://api.fda.gov/drug/label.json?search=id%3A%221203ca7f-080c-4c49-e063-6294a90a90e0%22

spl effective date

2024-02-22

spl set id

74e5060c-8426-1b77-e053-2a91aa0a1f13

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 11 · unclassified context

application numbers

NDA011856

brand names

SOLU-MEDROL

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2702
end exclusive: true
exact text: lar inflammatory conditions unresponsive to topical corticosteroids. Renal diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spon
label id: 1203ca7f-080c-4c49-e063-6294a90a90e0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 00e900f60d9223601eb11bbc92ed46381adad7b793770517b64e5bb78b5264b5
start: 2087

current approval status

not_reconciled

duplicate text group

dup-d321ab32d081d2081625

extraction review status

automated_candidate_pending_source_review

generic names

SOLU-MEDROL

ind-span-125bdb30e7e8decd15b3

label id

1203ca7f-080c-4c49-e063-6294a90a90e0

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 2502
end exclusive: true
exact text: Respiratory diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis.
label id: 1203ca7f-080c-4c49-e063-6294a90a90e0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 00e900f60d9223601eb11bbc92ed46381adad7b793770517b64e5bb78b5264b5
start: 2287

source url

https://api.fda.gov/drug/label.json?search=id%3A%221203ca7f-080c-4c49-e063-6294a90a90e0%22

spl effective date

2024-02-22

spl set id

74e5060c-8426-1b77-e053-2a91aa0a1f13

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 12 · unclassified context

application numbers

NDA011856

brand names

SOLU-MEDROL

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2958
end exclusive: true
exact text: ases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, temporal arteritis, polymyositis, and systemic lupus erythematosus.
label id: 1203ca7f-080c-4c49-e063-6294a90a90e0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 00e900f60d9223601eb11bbc92ed46381adad7b793770517b64e5bb78b5264b5
start: 2303

current approval status

not_reconciled

duplicate text group

dup-bf3a6bac6b0740eefcad

extraction review status

automated_candidate_pending_source_review

generic names

SOLU-MEDROL

ind-span-b8baecffa4c3ec48e9ce

label id

1203ca7f-080c-4c49-e063-6294a90a90e0

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 2852
end exclusive: true
exact text: Rheumatic disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy).
label id: 1203ca7f-080c-4c49-e063-6294a90a90e0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 00e900f60d9223601eb11bbc92ed46381adad7b793770517b64e5bb78b5264b5
start: 2503

source url

https://api.fda.gov/drug/label.json?search=id%3A%221203ca7f-080c-4c49-e063-6294a90a90e0%22

spl effective date

2024-02-22

spl set id

74e5060c-8426-1b77-e053-2a91aa0a1f13

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 13 · unclassified context

application numbers

NDA011856

brand names

SOLU-MEDROL

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2958
end exclusive: true
exact text: hritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, temporal arteritis, polymyositis, and systemic lupus erythematosus.
label id: 1203ca7f-080c-4c49-e063-6294a90a90e0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 00e900f60d9223601eb11bbc92ed46381adad7b793770517b64e5bb78b5264b5
start: 2653

current approval status

not_reconciled

duplicate text group

dup-a019d33f39e129a34356

extraction review status

automated_candidate_pending_source_review

generic names

SOLU-MEDROL

ind-span-5dfdf305787a97f77535

label id

1203ca7f-080c-4c49-e063-6294a90a90e0

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 2958
end exclusive: true
exact text: For the treatment of dermatomyositis, temporal arteritis, polymyositis, and systemic lupus erythematosus.
label id: 1203ca7f-080c-4c49-e063-6294a90a90e0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 00e900f60d9223601eb11bbc92ed46381adad7b793770517b64e5bb78b5264b5
start: 2853

source url

https://api.fda.gov/drug/label.json?search=id%3A%221203ca7f-080c-4c49-e063-6294a90a90e0%22

spl effective date

2024-02-22

spl set id

74e5060c-8426-1b77-e053-2a91aa0a1f13

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Preserved source evidence · Not medical advice